Summary
Vindesine (VDS) is an analogue of the vinca alkaloids. Its spectrum of antitumoral activity is similar to that of vincristine (VCR), but with milder experimental neurotoxicity, and it inhibits the polymerization of tubulin. Its terminal half-life is 24 h and its plasma clearance is intermediate between those of vinblastine (VLB) and VCR. The maximal tolerated dose is 4–5 mg/m2/week, the dose-limiting toxicity being myelosuppression (nadir by days 7–8 and recovery by days 11–13). It has already been demonstrated as efficient in childhood acute lymphoid leukemia (ALL), non-Hodgkin’s lymphoma, blastic crisis of chronic myeloid leukemia, and esophageal carcinoma. It has also shown activity in Hodgkin’s disease, breast and germ cell carcinomas, and melanoma. Intolerance is mainly neurologic, with paresthesias, without motor impairment, or hematologic, with leukopenia, and sometimes alopecia, asthenia, and muscle pains. The results are better if the patients have not been treated previously; continuous infusion could be of interest and there appears to be no cross-resistance with its parent VCR, as documented in ALL.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Barnett CJ, Cullinan GJ, Gerzon K, Hoying, RC, Jones WE, Newlon WM, Poore GA, Robinson RL, Sweeney MJ, Todd GC, Dyke RW, Nelson RL (1978) Structure-activity relationship of dimeric Catharanthus alkaloids. I. Desacetylvinblastine amide (vindesine) sulfate. J Med Chem 21:88–96
Bayssas M, Gouveia J, Ribaud P, Musset M, De Vassal F, Pico JL, De Luca L, Misset JL, Machover D, Belpomme D, Schwarzenberg L, Jasmin C, Hayat M, Mathe G (1979) Phase-II trial with vindesine for regression induction in patients with leukemias and hematosarcomas. Cancer Chemother Pharmacol 2:247–255
Bedikian AY, Valdivieso M, Bodey GP, Freireich EJ (1979) Phase II evaluation of vindesine in the treatment of colorectal and esophageal tumors. Cancer Chemother Pharmacol 2:263–266
Casper ES, Gralla RJ, Golbey RB (1979) Vindesine (DVA) and cis-dichloro diammine platinum II (DDP) combination chemotherapy in non-small cell lung cancer (abstr C-190). Proc Am Soc Clin Oncol 20:337
Currie VE, Wong P, Krakoff IH, Young CW (1978) Phase I trial of vindesine in patients with advanced cancer. Cancer Treat Rep 62:1333–1336
Dyke RW, Nelson RL (1977) Phase I anti-cancer agents. Vindesine (desacetyl vinblastine amide sulfate). Cancer Treat Rev 4:135–142
Dyke RW, Nelson RL, Brade WP (1979) Vindesine. A short review of preclinical and first clinical data. Cancer Chemother Pharmacol 2:229–232
Gralla RJ, Tan CTC, Young CW (1979) Vindesine. A review of phase-II trials. Cancer Chemother Pharmacol 2:271–274
Himes RH, Kersey RN, Heller-Bettinger I, Samson FE (1976) Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide in microtubules in vitro. Cancer Res 36:3798–3802
Kelsen DP, Bains M, Golbey R, Woodcock T (1979) Vindesine in the treatment of esophageal carcinoma (abstr C-193). Proc Am Soc Clin Oncol 20:338
Krivit W, Chilcote R, Pyesmany A, Anderson J, Hammond D (1979) An initial report of a phase-Ill trial comparing vindesine and vincristine for acute lymphocytic leukemia of childhood. Cancer Chemother Pharmacol 2:267–270
Paintrand MR, Dantchev D, Bayssas M, Bourut C, Reiss F, Hayat M, Mathe G (to be published) Comparative actions of vindesine, vinblastine and vincristine in an electron microscopical study in mice, using P388 leukemic cells. Europ J Cancer
Retsas S, Newton KA, Westbury G (1979) Vindesine as a single agent in the treatment of advanced malignant melanoma. Cancer Chemother Pharmacol 2:257–260
Reynolds TF, Cvitkovic E, Golbey RB, Young CW (1979) Trial of vindesine (DVA) in patients with germ cell tumors (abstr C-196). Proc Am Soc Clin Oncol 20:338
Smith IE, Hedley DW, Powles TJ, McElwain TJ (1978) Vindesine: A phase II study in the treatment of breast carcinoma, malignant melanoma, and other tumors. Cancer Treat Rep 62:1427–1433
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1980 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Bayssas, M. et al. (1980). Vindesine: A New Vinca Alkaloid. In: Mathé, G., Muggia, F.M. (eds) Cancer Chemo- and Immunopharmacology. Recent Results in Cancer Research, vol 74. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81488-4_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-81488-4_13
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81490-7
Online ISBN: 978-3-642-81488-4
eBook Packages: Springer Book Archive